Bellevue Life Sciences Acquisition Corp. Files 8-K

TL;DR

Bellevue Life Sciences Acquisition Corp. filed an 8-K on July 11, 2024, detailing material agreements and financial obligations.

AI Summary

Bellevue Life Sciences Acquisition Corp. filed an 8-K on July 16, 2024, reporting a material definitive agreement and other events as of July 11, 2024. The filing details the company's structure, including units consisting of common stock, redeemable warrants, and rights, and its financial obligations.

Why It Matters

This 8-K filing provides crucial updates on Bellevue Life Sciences Acquisition Corp.'s material agreements and financial obligations, impacting investors' understanding of the company's structure and potential future transactions.

Risk Assessment

Risk Level: low — The filing is a routine 8-K reporting material definitive agreements and other events, without immediate news of significant financial distress or major strategic shifts.

Key Numbers

• 11.50 — Exercise Price (Per share exercise price for redeemable warrants)

Key Players & Entities

• Bellevue Life Sciences Acquisition Corp. (company) — Filer of the 8-K report
• July 11, 2024 (date) — Earliest event reported date
• July 16, 2024 (date) — Filing date of the 8-K
• 001-41390 (company) — SEC File Number for Bellevue Life Sciences Acquisition Corp.

FAQ

Key Financial Figures

• $0.0001 — ck Market LLC Common stock, par value $0.0001 per share BLAC The Nasdaq Stock Mar
• $11.50 — of common stock at an exercise price of $11.50 per share BLACW The Nasdaq Stock Ma
• $300,000 — sory Note ") in the principal amount of $300,000 to Bellevue Global Life Sciences Invest
• $50,000 — 8.01. Other Events. On July 12, 2024, $50,000 was deposited in the trust account in c

Filing Documents

• d867483d8k.htm (8-K) — 32KB
• d867483dex101.htm (EX-10.1) — 19KB
• 0001193125-24-179674.txt ( ) — 238KB
• blacu-20240711.xsd (EX-101.SCH) — 5KB
• blacu-20240711_def.xml (EX-101.DEF) — 15KB
• blacu-20240711_lab.xml (EX-101.LAB) — 26KB
• blacu-20240711_pre.xml (EX-101.PRE) — 16KB
• d867483d8k_htm.xml (XML) — 9KB

From the Filing

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 11, 2024 BELLEVUE LIFE SCIENCES ACQUISITION CORP. (Exact Name of Registrant as Specified in Charter) Delaware 001-41390 84-5052822 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 10900 NE 4th Street , Suite 2300 , Bellevue , WA 98004 (Address of Principal Executive Offices) (Zip Code) Registrant's telephone number, including area code (425) 635-7700 Not Applicable (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e 4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Units, each consisting of one share of common stock, one redeemable warrant and one right BLACU The Nasdaq Stock Market LLC Common stock, par value $0.0001 per share BLAC The Nasdaq Stock Market LLC Redeemable warrants, exercisable for shares of common stock at an exercise price of $11.50 per share BLACW The Nasdaq Stock Market LLC Right to receive one-tenth (1/10) of one share of common stock BLACR The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item1.01. Entry into a Material Definitive Agreement. The information provided in Item 2.03 of this Current Report on Form 8-K is incorporated by reference into this Item 1.01. Item2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. On July 11, 2024, Bellevue Life Sciences Acquisition Corp. (the " Company ") issued an unsecured promissory note (the " Promissory Note ") in the principal amount of $300,000 to Bellevue Global Life Sciences Investors, LLC (" BGLSI "), the sponsor of the Company. The Promissory Note is not interest bearing and is payable in full on the earlier of: (i) December 31, 2024 or (ii) the date on which the Company consummates an initial business combination (the " Maturity Date " ) . In the event that the Company does not consummate a business combination on or prior to the time provided in the Company's Amended and Restated Certificate of Incorporation (as subject to extension), BGLSI agrees to forgive the principal balance of the Promissory Note, except to the extent of any funds remaining outside of the Company's trust account, if any. The following shall constitute an event of default: (i) a failure to pay the principal within five business days of the Maturity Date and (ii) the commencement of a voluntary or involuntary bankruptcy action. The foregoing description of the Promissory Note is qualified in its entirety by reference to the full text of the Promissory Note, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference. Item8.01. Other Events. On July 12, 2024, $50,000 was deposited in the trust account in connection with the extension of the date by which the Company must consummate a business combination. Item9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1 Promissory Note, dated July 11, 2024, issued by Bellevue Life Sciences Acquisition Corp. to Bellevue Global Life Sciences Investors, LLC 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: July 16, 2024 BELLEVUE LIFE SCIENCES ACQUISITION CORP. By: /s/ Kuk Hyoun Hwang Name: Kuk Hyoun Hwang Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR